Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
Mr. Drysdale’s fireside chat will be webcast live on Tuesday, August 12, 2025, at 2:30 p.m. ET. To listen to the event, please to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the page.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in
View source version on businesswire.com:
Investor & Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
[email protected] � or � [email protected]
Source: Cybin Inc.
